The brain-gut-microbiome axis has become a central focus in understanding the bidirectional interactions between the gut microbiome and the brain. Recent research highlights the role of this axis in various neurological and psychiatric disorders, including irritable bowel syndrome (IBS), obesity, and Parkinson's disease. The gut microbiota communicates with the central nervous system through nervous, endocrine, and immune signaling pathways, influencing brain function and behavior. Preclinical studies show that gut microbes can affect brain development, mood, and behavior, while the brain can also influence gut microbiota through the autonomic nervous system. A systems biological model suggests that disruptions in this axis can lead to dysregulation in brain-gut interactions, contributing to disease pathogenesis. The gut microbiome plays a crucial role in modulating neurochemical processes, such as serotonin production and regulation, which are essential for gut function and brain health. Gut microbes produce metabolites like short-chain fatty acids (SCFAs) and secondary bile acids that influence brain signaling through enteroendocrine cells and the immune system. These molecules can cross the blood-brain barrier and affect brain function. Additionally, the gut microbiota influences the production of neuroactive compounds, including serotonin, which is vital for mood regulation. The gut-brain axis is also involved in the pathophysiology of psychiatric disorders such as depression and anxiety. Preclinical studies have shown that gut microbiota can modulate emotional behaviors and influence parameters related to depression. Clinical studies suggest that probiotics and prebiotics may have therapeutic potential in improving mood and reducing anxiety symptoms. However, the translation of these findings to human applications remains challenging due to differences in microbiota composition and host responses. The gut microbiome also plays a role in neurodevelopment and neuroinflammation, with implications for conditions like autism spectrum disorder and Parkinson's disease. The microbiome's influence on the brain-gut axis is complex, involving both direct and indirect signaling pathways. Future research aims to develop targeted therapies based on microbiome modulation, leveraging advances in metagenomics and computational biology to better understand the interactions within this axis. The next decade is expected to see increased integration of the gut microbiome into diagnostic and therapeutic approaches for various diseases.The brain-gut-microbiome axis has become a central focus in understanding the bidirectional interactions between the gut microbiome and the brain. Recent research highlights the role of this axis in various neurological and psychiatric disorders, including irritable bowel syndrome (IBS), obesity, and Parkinson's disease. The gut microbiota communicates with the central nervous system through nervous, endocrine, and immune signaling pathways, influencing brain function and behavior. Preclinical studies show that gut microbes can affect brain development, mood, and behavior, while the brain can also influence gut microbiota through the autonomic nervous system. A systems biological model suggests that disruptions in this axis can lead to dysregulation in brain-gut interactions, contributing to disease pathogenesis. The gut microbiome plays a crucial role in modulating neurochemical processes, such as serotonin production and regulation, which are essential for gut function and brain health. Gut microbes produce metabolites like short-chain fatty acids (SCFAs) and secondary bile acids that influence brain signaling through enteroendocrine cells and the immune system. These molecules can cross the blood-brain barrier and affect brain function. Additionally, the gut microbiota influences the production of neuroactive compounds, including serotonin, which is vital for mood regulation. The gut-brain axis is also involved in the pathophysiology of psychiatric disorders such as depression and anxiety. Preclinical studies have shown that gut microbiota can modulate emotional behaviors and influence parameters related to depression. Clinical studies suggest that probiotics and prebiotics may have therapeutic potential in improving mood and reducing anxiety symptoms. However, the translation of these findings to human applications remains challenging due to differences in microbiota composition and host responses. The gut microbiome also plays a role in neurodevelopment and neuroinflammation, with implications for conditions like autism spectrum disorder and Parkinson's disease. The microbiome's influence on the brain-gut axis is complex, involving both direct and indirect signaling pathways. Future research aims to develop targeted therapies based on microbiome modulation, leveraging advances in metagenomics and computational biology to better understand the interactions within this axis. The next decade is expected to see increased integration of the gut microbiome into diagnostic and therapeutic approaches for various diseases.